EBITDA Margin % is calculated as EBITDA divided by its Revenue. Soligenix's EBITDA for the
three
months ended in Dec. 2023 was $-2.32 Mil. Soligenix's Revenue for the
three
months ended in Dec. 2023 was $0.00 Mil. Therefore, Soligenix's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.
Soligenix EBITDA Margin % Historical Data
The historical data trend for Soligenix's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Soligenix's EBITDA Margin %
For the Biotechnology subindustry, Soligenix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soligenix's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soligenix's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Soligenix's EBITDA Margin % falls into.
Soligenix EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Soligenix's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soligenix (NAS:SNGX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Soligenix EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Soligenix's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNGX has been successfully added to your 